Free Trial

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Mirum Pharmaceuticals logo
$52.87 -0.29 (-0.54%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Key Stats

Today's Range
$52.55
$54.23
50-Day Range
$40.60
$53.16
52-Week Range
$23.14
$54.23
Volume
203,062 shs
Average Volume
503,514 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.10
Consensus Rating
Buy

Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

MIRM MarketRank™: 

Mirum Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 503rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mirum Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Mirum Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mirum Pharmaceuticals is -26.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mirum Pharmaceuticals is -26.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mirum Pharmaceuticals has a P/B Ratio of 10.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mirum Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.69% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently decreased by 1.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Mirum Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Mirum Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.69% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently decreased by 1.20%, indicating that investor sentiment is improving.
  • News Sentiment

    Mirum Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,897,920.00 in company stock.

  • Percentage Held by Insiders

    22.87% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Mirum Pharmaceuticals' insider trading history.
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Stock News Headlines

A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
US FDA approves Mirum Pharma's genetic disorder drug
Mirum Pharmaceuticals
See More Headlines

MIRM Stock Analysis - Frequently Asked Questions

Mirum Pharmaceuticals' stock was trading at $41.35 at the start of the year. Since then, MIRM stock has increased by 29.8% and is now trading at $53.69.
View the best growth stocks for 2025 here
.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm's revenue for the quarter was up 89.4% compared to the same quarter last year.

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Mirum Pharmaceuticals' top institutional investors include Janus Henderson Group PLC (9.54%), BVF Inc. IL (5.82%), Vanguard Group Inc. (5.05%) and Rock Springs Capital Management LP (3.07%). Insiders that own company stock include Niall O'donnell, James E Flynn, Patrick J Heron, Christopher Peetz, Lara Longpre, Pamela Vig, Peter Radovich, Joanne Quan, Jolanda Howe and Michael G Grey.
View institutional ownership trends
.

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
11/12/2024
Today
2/21/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.10
High Stock Price Target
$68.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+7.4%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Net Income
$-163,410,000.00
Pretax Margin
-31.91%

Debt

Sales & Book Value

Annual Sales
$186.37 million
Book Value
$5.33 per share

Miscellaneous

Free Float
37,026,000
Market Cap
$2.55 billion
Optionable
Optionable
Beta
0.96
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MIRM) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners